Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

Requip tablets treat symptoms of primary RLS

17.12.2004


Study shows GSK’s Requip improves sleep and quality of life in patients

... mehr zu:
»CGI-I »IRLS »RLS

Research Triangle Park, NC (December 15, 2004) – Study results published today in the journal Movement Disorders show that Requipâ(ropinirole HCl) Tablets effectively treats the symptoms of primary Restless Legs Syndrome (RLS) as assessed by improvements in symptoms, over 12 weeks. Improvements were seen as early as one week. The study of 267 patients, one of the largest placebo-controlled trials of a treatment for RLS conducted to-date, also showed significant improvements in sleep and quality of life in RLS patients taking Requip versus placebo. Requip is under review by the U.S. Food and Drug Administration (FDA) for the treatment of the signs and symptoms of primary RLS. There is no FDA-approved treatment for RLS in the United States.

"Patients with Restless Legs Syndrome often suffer from chronic sleep problems as a result of an urge to move their legs, often accompanied by discomfort or unpleasant feelings in their legs. This sleep disruption is one of the most distressing aspects of the condition and can greatly impact quality of life," said Arthur S. Walters, M.D., Director of the Center for Sleep Disorders Treatment, Research and Education at the New Jersey Neuroscience Institute at John F. Kennedy Medical Center. "These study results are encouraging because they provide evidence that Requip significantly improved symptoms of RLS at one week. Patients experienced improvements in sleep and quality of life."


Restless Legs Syndrome is a common and disruptive neurological condition characterized by an irresistible urge to move the legs and by uncomfortable or sometimes painful sensations in the legs often described as creeping-crawling, burning or twitching. Symptoms of RLS generally occur at rest, such as when sitting, lying or sleeping, and are temporarily relieved by movement. These symptoms can significantly disrupt a patient’s sleep and daily activities. People with RLS often have difficulty falling and staying asleep and can feel less alert during the day. RLS sufferers may also have difficulty with activities that require prolonged sitting such as movies, long car rides or airline flights. When evaluating patients’ symptoms of RLS, it is important for healthcare providers to rule out other underlying conditions that are associated with secondary RLS symptoms, such as iron deficiency, pregnancy and renal failure.

Significant and Sustained Relief from RLS Symptoms

Patients in this trial experienced significant improvement in their symptoms at one week of treatment with Requip, continuing through week 12. In total, 267 patients ages 18-79, with moderate-to-severe primary RLS, were randomized to Requip (0.25-4.0 mg/day) or placebo, 1-3 hours before bedtime. The primary endpoint was the change in International RLS Rating Scale (IRLS Scale) score at week 12. Improvements were significantly better for Requip than placebo on the IRLS Scale (–11.2 vs. –8.7; p = 0.0197).

Key secondary endpoints were the percentage of patients showing significant improvement on the Clinical Global Impression–Improvement (CGI-I) scale at week 12, and changes in their IRLS Scale and CGI-I scale scores at week one. At week 12, significantly more patients treated with Requip (78/131, 59.5 percent) responded "much improved" or "very much improved" on the CGI-I scale compared with those treated with placebo (53/134, 39.6 percent; p = 0.001).

In addition, patients taking Requip showed significant improvement from baseline in the IRLS Scale score at the end of week one (–8.4 vs. –4.8; p< 0.0001). On the CGI-I scale, more patients taking Requip (48/131, 36.6 percent) than those taking placebo (22/134, 16.4 percent) responded "much improved" or "very much improved" after one week (p = 0.0003).

Requip® Improves Sleep and Quality of Life

Patients taking Requip showed significant improvements in sleep as measured in all four domains of the Medical Outcomes Study (MOS) sleep scale at week 12 (somnolence, p = 0.0043; sleep disturbance, p< 0.0001; sleep adequacy, p< 0.0001; sleep quantity, p= 0.0097). According to the study authors, this means patients taking Requip slept more soundly (with less disturbance), for a longer time, perceived their sleep adequacy was improved and were less sleepy during the daytime than those taking placebo.

There were also improvements in patients’ quality of life (QoL), assessed using the disease-specific RLS QoL questionnaire. At week 12, the overall life-impact score showed a significant difference in favor of Requip (increased 17.4 points) over placebo (increased 12.9 points; p = 0.0263). Using a general QoL scale (SF-36 Health Survey), there was a significant difference in favor of Requip for mental-health, social functioning and vitality. Values for physical functioning, bodily pain, role-physical, role-emotional and general health were not significantly different between the two treatment groups.

"I suffer from Restless Legs Syndrome and found that getting to sleep was difficult because I needed to move my legs in order to relieve the unpleasant sensations in the legs," stated study participant Kim McLawhon. "Staying asleep was also challenging because my leg movements disturbed my sleep and I never felt rested in the morning. But being in the clinical trial and taking Requip helped to control my symptoms so that I got more sleep at night."

During treatment over a twelve-week period and over the dose range of 0.25 – 4 mg/day, the most commonly reported adverse events of Requip (n=131) versus placebo (n=136) were nausea (39.7 percent vs. 8.1 percent), headache (22.1 percent vs. 25.7 percent), fatigue (15.3 percent vs. 6.6 percent), dizziness (15.3 percent vs. 4.4 percent) and vomiting (12.2 percent vs. 2.2 percent).

About Requip®

Requip is a second-generation non-ergoline dopamine agonist that directly stimulates dopamine receptors in the brain. While the exact cause of primary RLS is unknown, doctors believe it is caused by a lack of dopamine, a chemical that carries the signals between the nerve cells that control movement.

Requip is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease and is generally well-tolerated in this population. In placebo-controlled studies for early treatment in this patient population, the most commonly reported side effects for Requip versus placebo were nausea (60 percent versus 22 percent), dizziness (40 percent versus 22 percent) and somnolence (40 percent versus 6 percent). Patients are advised to talk to their doctor about whether they have the potential to develop the sedating effects associated with Requip, which include somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Fainting or low blood pressure may occur during initial treatment or with an increase in dose. Hallucinations may occur at anytime during treatment. Requip may potentiate the side effects of L-dopa and may cause and/or exacerbate pre-existing dyskinesias.

About GlaxoSmithKline

GlaxoSmithKline is one of the world’s leading research-based pharmaceutical and healthcare companies. Please consult full prescribing information for Requip, available at www.Requip.com. For more information on GlaxoSmithKline, call 1-888-825-5249 or visit www.gsk.com.

Christina Corso | EurekAlert!

Weitere Berichte zu: CGI-I IRLS RLS

Weitere Nachrichten aus der Kategorie Medizin Gesundheit:

nachricht Neuer Ansatz gegen Gastritis
10.08.2017 | Medizinische Hochschule Hannover

nachricht Wenn Schimmelpilze das Auge zerstören
10.08.2017 | Julius-Maximilians-Universität Würzburg

Alle Nachrichten aus der Kategorie: Medizin Gesundheit >>>

Die aktuellsten Pressemeldungen zum Suchbegriff Innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Unterwasserroboter soll nach einem Jahr in der arktischen Tiefsee auftauchen

Am Dienstag, den 22. August wird das Forschungsschiff Polarstern im norwegischen Tromsø zu einer besonderen Expedition in die Arktis starten: Der autonome Unterwasserroboter TRAMPER soll nach einem Jahr Einsatzzeit am arktischen Tiefseeboden auftauchen. Dieses Gerät und weitere robotische Systeme, die Tiefsee- und Weltraumforscher im Rahmen der Helmholtz-Allianz ROBEX gemeinsam entwickelt haben, werden nun knapp drei Wochen lang unter Realbedingungen getestet. ROBEX hat das Ziel, neue Technologien für die Erkundung schwer erreichbarer Gebiete mit extremen Umweltbedingungen zu entwickeln.

„Auftauchen wird der TRAMPER“, sagt Dr. Frank Wenzhöfer vom Alfred-Wegener-Institut, Helmholtz-Zentrum für Polar- und Meeresforschung (AWI) selbstbewusst. Der...

Im Focus: Mit Barcodes der Zellentwicklung auf der Spur

Darüber, wie sich Blutzellen entwickeln, existieren verschiedene Auffassungen – sie basieren jedoch fast ausschließlich auf Experimenten, die lediglich Momentaufnahmen widerspiegeln. Wissenschaftler des Deutschen Krebsforschungszentrums stellen nun im Fachjournal Nature eine neue Technik vor, mit der sich das Geschehen dynamisch erfassen lässt: Mithilfe eines „Zufallsgenerators“ versehen sie Blutstammzellen mit genetischen Barcodes und können so verfolgen, welche Zelltypen aus der Stammzelle hervorgehen. Diese Technik erlaubt künftig völlig neue Einblicke in die Entwicklung unterschiedlicher Gewebe sowie in die Krebsentstehung.

Wie entsteht die Vielzahl verschiedener Zelltypen im Blut? Diese Frage beschäftigt Wissenschaftler schon lange. Nach der klassischen Vorstellung fächern sich...

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Forscher entwickeln maisförmigen Arzneimittel-Transporter zum Inhalieren

Er sieht aus wie ein Maiskolben, ist winzig wie ein Bakterium und kann einen Wirkstoff direkt in die Lungenzellen liefern: Das zylinderförmige Vehikel für Arzneistoffe, das Pharmazeuten der Universität des Saarlandes entwickelt haben, kann inhaliert werden. Professor Marc Schneider und sein Team machen sich dabei die körpereigene Abwehr zunutze: Makrophagen, die Fresszellen des Immunsystems, fressen den gesundheitlich unbedenklichen „Nano-Mais“ und setzen dabei den in ihm enthaltenen Wirkstoff frei. Bei ihrer Forschung arbeiteten die Pharmazeuten mit Forschern der Medizinischen Fakultät der Saar-Uni, des Leibniz-Instituts für Neue Materialien und der Universität Marburg zusammen Ihre Forschungsergebnisse veröffentlichten die Wissenschaftler in der Fachzeitschrift Advanced Healthcare Materials. DOI: 10.1002/adhm.201700478

Ein Medikament wirkt nur, wenn es dort ankommt, wo es wirken soll. Wird ein Mittel inhaliert, muss der Wirkstoff in der Lunge zuerst die Hindernisse...

Im Focus: Exotische Quantenzustände: Physiker erzeugen erstmals optische „Töpfe" für ein Super-Photon

Physikern der Universität Bonn ist es gelungen, optische Mulden und komplexere Muster zu erzeugen, in die das Licht eines Bose-Einstein-Kondensates fließt. Die Herstellung solch sehr verlustarmer Strukturen für Licht ist eine Voraussetzung für komplexe Schaltkreise für Licht, beispielsweise für die Quanteninformationsverarbeitung einer neuen Computergeneration. Die Wissenschaftler stellen nun ihre Ergebnisse im Fachjournal „Nature Photonics“ vor.

Lichtteilchen (Photonen) kommen als winzige, unteilbare Portionen vor. Viele Tausend dieser Licht-Portionen lassen sich zu einem einzigen Super-Photon...

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

European Conference on Eye Movements: Internationale Tagung an der Bergischen Universität Wuppertal

18.08.2017 | Veranstaltungen

Einblicke ins menschliche Denken

17.08.2017 | Veranstaltungen

Eröffnung der INC.worX-Erlebniswelt während der Technologie- und Innovationsmanagement-Tagung 2017

16.08.2017 | Veranstaltungen

 
VideoLinks
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Eine Karte der Zellkraftwerke

18.08.2017 | Biowissenschaften Chemie

Chronische Infektionen aushebeln: Ein neuer Wirkstoff auf dem Weg in die Entwicklung

18.08.2017 | Biowissenschaften Chemie

Computer mit Köpfchen

18.08.2017 | Informationstechnologie